[
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
    "id": "02975666",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
    "summary": "<ul>\n<li><strong>R&amp;D Pipeline</strong>: Targets global addressable markets worth &gt;US$8bn; 8 patented products in active R&amp;D, plus 24 off-patent injectables and improved migraine treatment in development.  </li>\n<li><strong>FY26 Guidance</strong>: Confirmed operating profit forecast of <strong>A$20\u201324m</strong>; on track for <strong>FY27 revenue target of A$300m</strong>.  </li>\n<li><strong>Commercialisation Progress</strong>: 5 advanced R&amp;D programs entering global markets, including Maxigesic\u00ae variants, Crystaderm\u00ae, Micolette\u00ae, Kiwisoothe\u00ae, and capsaicin cream.  </li>\n</ul>\n<p><em>No material trading or capital markets actions (e.g., raising, dividends) announced. Focus is strategic/growth outlook.</em></p>",
    "usage": {
      "prompt_tokens": 1072,
      "completion_tokens": 149,
      "total_tokens": 1221,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:58:39.269991"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
    "id": "02975667",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
    "summary": "<ul>\n<li><strong>Revenue milestone</strong>: FY revenue reached <strong>$208 million</strong>, exceeding $200 million for the first time.  </li>\n<li><strong>Geographic expansion</strong>: Strong Australasian sales ($181M); progress in North America (US &amp; Canada), Europe, Asia, and Africa.  </li>\n<li><strong>US/Canada</strong>: Launched Maxigesic IV/tablet; combined addressable market <strong>&gt;US$8 billion</strong>.  </li>\n<li><strong>Product pipeline</strong>: 8 patented products in R&amp;D, 24 off-patent injectables, and 5 advanced programs nearing commercialization.  </li>\n<li><strong>Financials</strong>: Net debt reduced to <strong>$14.5M</strong> (from $16.2M); dividend increased to <strong>1.8cps</strong> (from 1.6cps).  </li>\n<li><strong>FY27 target</strong>: Ambitious <strong>$300M revenue goal</strong>, driven by market expansion and R&amp;D.  </li>\n<li><strong>Share price disconnect</strong>: Management believes current valuation undervalues growth prospects.  </li>\n</ul>\n<p><em>Omitted: Governance updates, operational details, and non-material strategic commentary.</em></p>",
    "usage": {
      "prompt_tokens": 1984,
      "completion_tokens": 216,
      "total_tokens": 2200,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:59:19.518191"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
    "id": "02975668",
    "pages": 30,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
    "summary": "<h3><strong>Summary of Material Information</strong></h3>\n<h4><strong>Financial &amp; Operational Highlights</strong></h4>\n<ul>\n<li><strong>FY25 Revenue</strong>: NZ$208.0M (6% YoY growth), with ANZ sales at NZ$180.9M.  </li>\n<li><strong>FY25 Operating Profit</strong>: NZ$17.6M (down from NZ$24.2M in FY24), impacted by lower license income (NZ$0.7M vs. NZ$8.5M) and 1H25 disruptions (Korean doctors\u2019 strike).  </li>\n<li><strong>Dividend</strong>: Increased to 1.8 cps (from 1.6 cps in FY24).  </li>\n<li><strong>Net Debt</strong>: Reduced to NZ$14.5M (from NZ$16.2M in FY24).  </li>\n<li><strong>Cash Flow</strong>: Closing cash balance not disclosed in extract; NZ EBITDA reconciliation shows NZ$20.9M for FY25.  </li>\n</ul>\n<h4><strong>Growth Targets &amp; Outlook</strong></h4>\n<ul>\n<li><strong>Revenue Target</strong>: NZ$300M by FY27.  </li>\n<li><strong>FY26 Operating Profit Guidance</strong>: NZ$20M\u2013NZ$24M.  </li>\n</ul>\n<h4><strong>Key Developments</strong></h4>\n<ul>\n<li><strong>International Expansion</strong>:  </li>\n<li>Products sold in nearly <strong>80 countries</strong>; revenue from global partnerships declined to NZ$15.4M (vs. NZ$19.3M in FY24) due to destocking.  </li>\n<li>Launches in new markets (UK, EU, Canada, South Africa, Hong Kong, Singapore).  </li>\n<li><strong>R&amp;D Pipeline</strong>:  </li>\n<li><strong>8 patented products</strong> in active development, including Maxigesic IV (pediatric filing 3Q26), Crystaderm (antibacterial), and Pascomer (no approved treatment).  </li>\n<li><strong>24+ injectable products</strong> under development.  </li>\n<li>R&amp;D spend: NZ$15.0M (FY25).  </li>\n</ul>\n<h4><strong>Governance</strong></h4>\n<ul>\n<li><strong>Resolutions Passed</strong>: Auditor remuneration, re-election of MD Hartley Atkinson, election of Allison Yorston (new independent director).  </li>\n</ul>\n<h4><strong>Material Risks/Omissions</strong></h4>\n<ul>\n<li>No explicit disclosure of <strong>cash balance</strong> or <strong>capital structure changes</strong> (e.g., issuance/buybacks).  </li>\n<li><strong>Forward-looking statements</strong> rely on commercialization success and market conditions.  </li>\n</ul>\n<p><strong>Format</strong>: Concise bullets tailored for trading/capital markets decisions. Omitted non-material details (e.g., director bios, operational minutiae).</p>",
    "usage": {
      "prompt_tokens": 5861,
      "completion_tokens": 500,
      "total_tokens": 6361,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:59:04.207955"
  }
]